

Shingles National Immunisation Programme

Programme Implementation Planning Tool

Prescribing information for **SHINGRIX (herpes zoster vaccine recombinant, adjuvanted)** can be found by scanning the QR code at the end of this handbook or speaking to your GSK representative.



Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com.

Eligibility for the Shingles National Immunisation Programme



Estimates suggest that **1 in 4** people in the UK will suffer from shingles in their lifetime¹




Shingles is a **painful disease** that can have serious and long-lasting complications²



Post-herpetic neuralgia (PHN), characterised by pain lasting longer than 3 months, affects up to 20% of patients **over 50 years old**³

How old is your patient?

Eligible

<p>years or older</p> <h1>50</h1> <p>with a severely weakened immune system* (severely immuno-compromised)</p> <p>They're eligible now</p> 	<p>years</p> <h1>65</h1> <p>Individuals who turned 65 on or after 1st September 2023 remain eligible until they turn 80.</p> 	<p>to years</p> <h1>70</h1> <h1>79</h1> <p>They're eligible now</p> 
<p>Under 50 with a severely weakened immune system</p>	<p>Under 65 - they will be eligible when they turn 65; Born before 1st Sept 1958 - they will be eligible when they turn 70</p>	<p>Over 80 without a severely weakened immune system</p>

Not eligible

*Patients receiving a stem cell transplant may be eligible from age 18.

References:

1. UKHSA Green Book: Chapter 28a Shingles. March 2024.
2. UK NICE Clinical Knowledge Summaries (Shingles), November 2024.
3. Gauthier A, et al. Epidemiol Infect. 2009;137(1):38-47.

iQuminate

A dedicated platform of support for Immunisation Leads and the wider immunisation team, providing peer-led education, practical resources and the opportunity to connect and collaborate with the wider Immunisation Lead community.

This website contains promotional information.
This initiative is organised and funded by GSK.
www.peersinpractice.gsk.com/iQuminate

SCAN HERE FOR MORE
IMPLEMENTATION SUPPORT



GSK

Shingles is a non-seasonal disease, and therefore organising shingles vaccination clinics regularly throughout the year can help protect patients as soon as they become eligible. Although opportunities to engage with eligible patients for the shingles vaccination at routine health checks or other scheduled vaccination appointments can help to increase uptake, potential benefits of having a dedicated vaccination clinic could include:

- Enabling a greater number of people to receive a specific vaccine within a given location and day
- Improved organisation of vaccine delivery and management of stock
- Increased overall efficiency of your practice's immunisation process

Do you have a dedicated shingles vaccination clinic at your practice?

Use this tool to support your practice in setting up your shingles vaccination clinics and to monitor your success in delivering the Shingles National Immunisation Programme (NIP) in your practice!

Section to be completed by the practice manager, immunisation lead or other relevant registered healthcare professional

Shingles National Immunisation Programme Implementation Planning Tool

Who will be involved in delivering the Shingles vaccination clinics?

Immunisation Lead Name:

Other Relevant Vaccination Staff Names:

What are your practice shingles vaccination targets?

Use this space to consider and outline some of your practice goals for shingles vaccination

What are the shingles vaccination clinic goals for your practice?

How many patients will you aim to vaccinate per week/month/quarter?

How often will you run searches of eligible patients?

Any other practice goals which are not directly related to shingles vaccination but need to be considered when setting up dedicated shingles vaccination clinics?

Who will track the programme's progress within your practice?

What tracking metrics will you use to determine whether your plans are working towards your practice goals?

How often will you review whether your shingles NIP implementation plans are working for your practice and update your plans if necessary?

Key Plan Review Dates:

Dates on which you will aim to review your practice's Shingles NIP implementation plans

Plan Created

Date

Review 1

Date

Review 2

Date

Review 3

Date

Review 4

Date

Review 5

Date

How many patients are eligible for shingles vaccination within your practice?

Who will identify eligible patients?

How often will searches be run?

Date of search

# Patients who turned 65 on or after 01/09/2023	#	#	#	#	#	#
# Patients aged 70-79	#	#	#	#	#	#
# Eligible severely immunocompromised patients	#	#	#	#	#	#
Total patients eligible	#	#	#	#	#	#
Total patients awaiting 1 st dose						
Total patients awaiting 2 nd dose	#	#	#	#	#	#

When will your shingles vaccination clinics be scheduled for?

TIP: As you call patients in for dedicated seasonal clinics, why not check if they are also eligible for the shingles vaccination, which can be given all year round?

Once an eligible patient is identified, we will aim to invite them for vaccination within _____ days/weeks.

Who will organise the vaccination clinics?

Clinic Date – 1st Dose

Appointments Available	#	#	#	#	#	#
Patients booked in	#	#	#	#	#	#
Total patients vaccinated per clinic	#	#	#	#	#	#

Have you scheduled the second dose for the shingles vaccination?

The shingles vaccination schedule consists of 2 doses, so it is important to ensure patients return for their second dose.

Who will be responsible for recalling patients for their 2nd dose?

How often will searches be run?

How will patients be recalled?

Clinic Date – 2nd Dose

Appointments available	#	#	#	#	#	#
Patients booked in	#	#	#	#	#	#
Total patients to be vaccinated per clinic	#	#	#	#	#	#

Additional Notes:

**For more support with the implementation of vaccine programmes,
become part of the illuminate community!**

Illuminate is organised and funded by GSK and contains promotional information.



Created with Immunisation Leads

Solution-focused content, created with a team of Immunisation Leads



Access Practical Tools

Up-to-date tools and resources, designed to support the professional development of you and your team



Share Your Challenges

Connect with experienced Immunisation Leads, to hear their expert insights and advice, to drive immunisation best practice



Visit Illuminate!

Prescribing information for Shingrix (herpes zoster vaccine recombinant, adjuvanted) can be accessed by scanning this QR code or by [clicking here](#)



Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com.